• Non ci sono risultati.

Scarica il programma

N/A
N/A
Protected

Academic year: 2022

Condividi "Scarica il programma"

Copied!
8
0
0

Testo completo

(1)
(2)

GIOVANNI APOLONE (Milan, Italy)

MATTEO BELLONE (Milan, Italy)

SILVIO BICCIATO (Modena, Italy) PAOLO BRUZZI (Genova, Italy)

PIERFRANCO CONTE (Padua, Italy)

FILIPPO DE BRAUD (Milan, Italy)

GIANNINO DEL SAL (Trieste, Italy)

MICHELE DEL VECCHIO (Milan, Italy)

MASSIMO DI NICOLA (Milan, Italy)

ALEXANDER EGGERMONT (Paris, France)

SOLDANO FERRONE (Boston, USA)

JOHN HISCOTT (Rome, Italy)

MICHAEL LISANTI (Salford, UK)

LUCA MAGNANI (London, UK)

ALBERTO MANTOVANI (Milan, Italy)

SAVERIO MINUCCI (Milan, Italy)

STEPHEN PETTITT (London, UK)

DIRK SCHADENDORF (Essen, Germany)

Under the patronage of FACULTY

2

(3)

The “10

th

Milan Congress on Anticancer Innovative Therapy”

will collect leading international experts in the field of immuno- oncology and cancer cell signaling to understand the potential, opportunities and challenges of the immunotherapy and targeted therapies.

The key role of the immune system in cancer has been recognized for a long time.

Our understanding of the co-evolution of cancer and the immune system has significantly improved, with significant results in clinic. Indeed, the increasing knowledge of the molecular mechanisms responsible for neoplastic transformation, the biology of cancer cells, and the immunological mechanisms regulating tumor-host interaction, allowed us to identify and apply more effective anti-cancer biogical and immunological treatments. To date, the immuno-biotherapy is a continuously evolving treatment modality and it is currently integrated into the treatment algorythms of several different tumor types.

Furthermore, elucidating resistance mechanismsand exploiting cancer vulnerabilities to therapeutics will ultimately improve cancer therapyand patient care.

This conference explores topics that will appeal to clinicians, as well as, basic, translational, and clinical scientists ranging from academics to industry. As in the past, the meeting will provide a highly interactive forum in which leading experts will discuss clinical and pre-clinical data, providing the audience with a broad overview of the most recent achievements in cancer biologic and immunologic therapy.

Finally, several data supporting the combination of immunothe- rapies and standard treatments open an intriguing challenge, but also a real opportunity for the future therapeutic approaches.

PRESENTATION

3

(4)

16.00-16.40 Registration

16.40-16.50 Welcome remarks of Scientific Director G. Apolone (Milan, Italy)

16.50-17.00 Introduction • M. Di Nicola (Milan, Italy)

17.00-17.30 Novel targets in anticancer treatment D. Schadendorf (Essen, Germany) Presented by M. Di Nicola (Milan, Italy)

17.30-18.00 LECTURE OF THE 10

TH

ANNIVERSARY:

Innate Immunity, Inflammation and Cancer:

double edged swords • A. Mantovani (Milan, Italy) Presented by M. Del Vecchio (Milan, Italy)

23 JANUARY 2020

4

(5)

09.00- 09.20 Registration

I SESSION: PRECLINICAL EVIDENCES AND NEW TARGETS Chairmen: F. de Braud (Milan, Italy), S. Ferrone (Boston, USA) 09.20-09.50 Diving in the dark matter of the breast cancer genome

L. Magnani (London, UK)

09.50-10.20 Eradicating Cancer Stem Cells (CSCs) with Anti-Mitochondrial Therapeutics: Pre-clinical Evidence and Clinical Trials

M. Lisanti (Salford, UK)

10.20-10.50 Synthetic Lethal Targeting of the DNA Damage Response: PARP inhibitors and beyond • S. Pettitt (London, UK)

10.50-11.10 General discussion 11.10-11.30 Coffee Break

11.30-12.00 NIBIT Lecture: Novel diagnostic and therapeutic targets in the crosstalk between prostate cancer stem-like cells and the tumor microenvironment • M. Bellone (Milan, Italy)

KEYNOTE LECTURE

12.00-12.30 p53 at the crossroads of mechano-signalling and metabolic pathways in cancer • G. Del Sal (Trieste, Italy)

Presented by M. Di Nicola (Milan, Italy) 12.30-13.30 Buffet Lunch

II SESSION: CLINICAL TRANSLATION

Chairmen: M. Del Vecchio (Milan, Italy), J. Hiscott (Rome, Italy)

13.30-14.00 Novel insights into tumor cell metabolism • S. Minucci (Milan, Italy) 14.00-14.30 Immunotherapy in Melanoma from advanced to adjuvant

to neoadjuvant • A. Eggermont (Paris, France)

14.30-15.00 New targets: new endpoints? • P. Bruzzi (Genova, Italy) 15.00-15.30 Integrative bioinformatics in precision oncology

S. Bicciato (Modena, Italy)

15.30-16.00 Targeted therapies: present and future • P. Conte (Padua, Italy) 16.00-16.30 AWARD FOR THE BEST ABSTRACT

16.30-16.45 Conclusions • M. Del Vecchio (Milan, Italy) 16.45-17.00 CME Questionnaire compilation

24 JANUARY 2020

5

(6)

CONGRESS VENUE

Aula Magna Gianni Bonadonna Fondazione IRCCS

Istituto Nazionale dei Tumori Via G. Venezian, 1 - MILAN

SCIENTIFIC COMMITTEE Filippo de Braud - Milan, Italy Michele Del Vecchio - Milan, Italy Massimo Di Nicola - Milan, Italy Gianpietro Dotti - Chapel Hill, USA Soldano Ferrone - Boston, USA John Hiscott - Rome, Italy

BEST ABSTRACT AWARD

having as its first author a Researcher

< of 35 years

Send by January 20, 2020 to [email protected]

ORGANIZING SECRETARIAT

Nadirex International Srl Via Riviera 39 · 27100 Pavia Tel. +39.0382.525714/35 Fax +39.0382.525736 E-mail: [email protected] www.nadirex.com

OFFICIAL LANGUAGE English

CME PROVIDER NR. 265 Nadirex International Srl CME

The request for CME credits has been submitted to the Italian Ministry of Health.

ID Nr. 265-279270 - CME credits: Nr. 7

• Nr. Of training hours: 7

• Educational goal: Nr. 2 Guidelines-Protocols-Procedures

• Type of event: Congress / Symposium / Conference / Seminary

The Congress is intended for the following figures:

- Physician

(Ematology, Infectious Diseases, Oncology, Internal Medicine, Transfusional Medicine) - Biologist

- Biomedical laboratory technician Participants: 100.

In order to obtain CME credits, participants have to:

• Attend 90% of the sessions scheduled in the Scientific Program

• Correctly fill in CME questionnaire (giving the 75% of correct answers)

• Belong to one of the figures for which the congress is intended

• Return the documentation filled-in and signed to the Organizing Secretariat

• Sign the attendance register at the beginning and at the end of the Congress.

The CME certificate will be sent by mail after the Congress to the address given on the personal data form.

REGISTRATION

The registration is free and includes:

• Partecipation in the conference work

• Congress Kit

• Certificate of Attendance

• CME credits Certificate

• Coffee breaks and lunch as scheduled

• Post event educational material REGISTRATION INSTRUCTIONS The Congress provides for a maximum of 100 participants.

Registration online at www.nadirex.com within January 20th, 2020.

The Organizing Secretariat will confirm the registration by email.

GENERAL INFORMATIONS

6

(7)

Fill in using capital letters and send to:

NADIREX INTERNATIONAL s.r.l.

Registration online: www.nadirex.com within: January 20th, 2020

PLEASE COMPLETE THE FOLLOWING DETAILS

REGISTRATION FORM

PHISYCIAN

BIOLOGIST

BIOMEDICAL LABORATORY TECHNICIAN

CME PROVIDER NR. 265 Nadirex International Srl ID Nr. 265-279270 - CME credits: Nr. 7

Participants: 100.

The Congress is intended for the following figures:

• Physician (Ematology, Infectious Diseases, Oncology, Internal Medicine, Transfusional Medicine)

• Biologist

• Biomedical laboratory technician

Name ...

Surname ...

Profession ...

Discipline ...

Specialized ...

Clinic/Institute ...

Division/Department ...

Address ...

Postal Code ... Town/City ... Province ...

Tel. ...

Fax ...

Mobile Tel. ...

E-mail ...

I authorise the use of my personal data in accordance with Legislative Decree 196/2003

Date ... Signature ...

(8)

WITH THE SUPPORT OF:

Riferimenti

Documenti correlati

17.00 - 17.25 Il ruolo delle terapie di combinazione per il paziente con melanoma metastatico: pratica attuale e direzioni future.. Michele

SCIENTIFIC COMMITTEE LAURA ABATE-DAGA Thoracic Unit-Medical Oncology IRCCS National Cancer Institute (INT), Milano FILIPPO DE BRAUD Università degli Studi di Milano

Giuseppe Di Lucca – IRCCS Ospedale San Raffaele (Milano, Italy) Massimo Di Nicola – IRCCS Istituto Nazionale dei Tumori (Milano, Italy) Claudio Doglioni – Università Vita-Salute

Anna Sapino IRCCS Tumor Center Candiolo, Tourin, Italy Vanesa Gregorc IRCCS San Raffaele Hospital, Milan, Italy Angela Santoni University of Rome Sapienza, Rome, Italy

Matteo Bellone (Milano, Italy) Marco Bregni (Milano, Italy) Vincenzo Bronte (Verona, Italy) Mario Paolo Colombo (Milano, Italy) Massimo Di Nicola (Milano, Italy).. Vincenzo

Antonietta Ancona Filippo Anelli Michele Battaglia Domenica Lorusso Evaristo Maiello Eugenio Maiorano Nicola Marzano Ciro Michele Niro Stefano Rinaldi Giammarco Surico Maria

Lichtman , Commak, NY, USA Maria Lia Lunardelli , Bologna, Italy Giovanni Martinelli , Bologna, Italy Graham Pawelec , Tübingen, Germany Umberto Ricardi , Turin, Italy. Michele Spina

Chairs: Michele Maio (Siena, Italy) and Matteo Bellone (Milan, Italy) 10:30 Sergio Quezada (London, UK): Clonal neoantigens elicit T cell immunoreactivity and sensitivity to